{"nctId":"NCT00490035","briefTitle":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","startDateStruct":{"date":"2007-09"},"conditions":["Epilepsy"],"count":399,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Brivaracetam 20 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam"]},{"label":"Brivaracetam 50 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam"]},{"label":"Brivaracetam 100 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Brivaracetam","otherNames":[]},{"name":"Brivaracetam","otherNames":[]},{"name":"Brivaracetam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted\n* Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification\n* Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)\n* Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1\n* Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period\n* Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED\n\nExclusion Criteria:\n\n* History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3\n* History or presence of status epilepticus during the year preceding Visit 1 or during Baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period","description":"Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null},{"groupId":"OG001","value":"1.34","spread":null},{"groupId":"OG002","value":"1.49","spread":null},{"groupId":"OG003","value":"1.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period","description":"Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.\n\nThe Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a \\>= 50 % reduction in seizure frequency per week from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"72.7","spread":null},{"groupId":"OG003","value":"64.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"27.3","spread":null},{"groupId":"OG003","value":"36.0","spread":null}]}]}]},{"type":"SECONDARY","title":"All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period","description":"There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null},{"groupId":"OG001","value":"1.34","spread":null},{"groupId":"OG002","value":"1.49","spread":null},{"groupId":"OG003","value":"1.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week","description":"The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) \\* 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.03","spread":null},{"groupId":"OG001","value":"-30.03","spread":null},{"groupId":"OG002","value":"-26.83","spread":null},{"groupId":"OG003","value":"-32.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period","description":"The categories are:\n\n* \\<= 25 %\n* \\- 25 % to \\< 25 %\n* 25 % to \\< 50 %\n* 50 % to \\< 75 %\n* 75 % to \\< 100 %\n* 100 %","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"15.2","spread":null},{"groupId":"OG003","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null},{"groupId":"OG001","value":"35.4","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"33.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"24.2","spread":null},{"groupId":"OG003","value":"21.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"18.2","spread":null},{"groupId":"OG002","value":"17.2","spread":null},{"groupId":"OG003","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"9.1","spread":null},{"groupId":"OG003","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period","description":"Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"99.0","spread":null},{"groupId":"OG003","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Type I Seizure During the 12-week Treatment Period","description":"The time to first Type I Seizure during the 12-week Treatment Period was measured in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Fifth Type I Seizure During the 12-week Treatment Period","description":"The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Tenth Type I Seizure During the 12-week Treatment Period","description":"The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.","description":"The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"62.5","spread":null},{"groupId":"OG003","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"14.03"},{"groupId":"OG001","value":"4.50","spread":"12.71"},{"groupId":"OG002","value":"3.09","spread":"14.43"},{"groupId":"OG003","value":"1.78","spread":"13.95"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":"22.01"},{"groupId":"OG001","value":"6.23","spread":"17.97"},{"groupId":"OG002","value":"5.34","spread":"23.81"},{"groupId":"OG003","value":"8.04","spread":"26.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.09","spread":"20.26"},{"groupId":"OG001","value":"3.35","spread":"19.72"},{"groupId":"OG002","value":"3.09","spread":"20.79"},{"groupId":"OG003","value":"3.50","spread":"22.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score","description":"The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"3.89"},{"groupId":"OG001","value":"-0.59","spread":"3.89"},{"groupId":"OG002","value":"-0.41","spread":"3.82"},{"groupId":"OG003","value":"0.08","spread":"3.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Hospital Depression Score","description":"The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"3.58"},{"groupId":"OG001","value":"-0.10","spread":"3.67"},{"groupId":"OG002","value":"0.26","spread":"3.84"},{"groupId":"OG003","value":"-0.24","spread":"3.69"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit","description":"The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: \"Overall, has there been a change in your seizures since the start of the study medication?\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","spread":"1.39"},{"groupId":"OG001","value":"5.17","spread":"1.27"},{"groupId":"OG002","value":"5.04","spread":"1.29"},{"groupId":"OG003","value":"5.47","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit","description":"The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: \"Assess the Overall change in the severity of patient's illness, compared to start of study medication.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":"1.20"},{"groupId":"OG001","value":"4.99","spread":"1.15"},{"groupId":"OG002","value":"4.99","spread":"1.10"},{"groupId":"OG003","value":"5.34","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.49","spread":"19.22"},{"groupId":"OG001","value":"3.53","spread":"17.04"},{"groupId":"OG002","value":"1.95","spread":"20.74"},{"groupId":"OG003","value":"1.99","spread":"20.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":"18.71"},{"groupId":"OG001","value":"3.75","spread":"15.94"},{"groupId":"OG002","value":"3.13","spread":"19.35"},{"groupId":"OG003","value":"-2.45","spread":"18.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"19.16"},{"groupId":"OG001","value":"5.36","spread":"20.69"},{"groupId":"OG002","value":"1.02","spread":"19.95"},{"groupId":"OG003","value":"0.69","spread":"16.66"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"28.93"},{"groupId":"OG001","value":"3.64","spread":"29.24"},{"groupId":"OG002","value":"-0.85","spread":"24.36"},{"groupId":"OG003","value":"3.00","spread":"28.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"18.48"},{"groupId":"OG001","value":"4.52","spread":"16.73"},{"groupId":"OG002","value":"4.55","spread":"18.93"},{"groupId":"OG003","value":"2.24","spread":"18.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score","description":"The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"16.3"},{"groupId":"OG001","value":"6.9","spread":"20.1"},{"groupId":"OG002","value":"9.7","spread":"19.8"},{"groupId":"OG003","value":"4.9","spread":"18.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":100},"commonTop":["Headache","Somnolence","Dizziness","Fatigue","Vertigo"]}}}